MedPath

Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Supernus' SPN-820 Shows Rapid Antidepressant Effects in Phase IIa Trial

• Supernus Pharmaceuticals' SPN-820 demonstrated rapid and substantial improvement in major depressive disorder (MDD) symptoms within two hours in a Phase IIa trial. • The study met its primary endpoint, showing a clinically meaningful improvement of -6.1 on the HAM-D6 scale at two hours, improving to -9.6 by day 10. • Suicidal ideation decreased significantly, from 12.5% at baseline to 2.6% on day ten, indicating a potential for rapid relief in at-risk patients. • SPN-820, an oral small molecule drug, enhances synaptic function by activating the mTORC1 pathway, offering a novel approach to treating depression.

Psilocybin Shows Promise as Alternative to SSRIs for Depression Treatment

• A recent study indicates that psilocybin, the active compound in magic mushrooms, offers comparable long-term benefits to escitalopram for treating depression. • Psilocybin outperformed escitalopram in enhancing psychosocial functioning, including a greater sense of meaning in life and improved social connectedness. • Researchers emphasize that psilocybin is still experimental and should only be administered in controlled environments due to potential risks. • Experts caution that not everyone is a candidate for psilocybin treatment, particularly those with a history of psychosis or bipolar disorder.

Psychedelics Show Promise in Treating Anxiety and Depression in Advanced Cancer Patients

• Psychedelic drugs, including psilocybin, LSD, and MDMA, may significantly alleviate depression and anxiety in advanced cancer patients, where conventional antidepressants often fall short. • A meta-analysis revealed that psychedelics reduced depression scores by six points and anxiety scores by seven to eight points, demonstrating a clinically meaningful improvement. • In a trial with cancer patients, 60% receiving psilocybin achieved depression remission, and 52% achieved anxiety remission, compared to 16% and 12% respectively with a placebo. • Psychedelic therapy may address underlying trauma associated with cancer diagnosis and treatment, offering a potential advantage over traditional antidepressants.
© Copyright 2025. All Rights Reserved by MedPath